21 June 2012 – Medical Research Network (MRN), a Clinical Trial Support Organisation (CTSO) offering home trial and site nurse support as well as bespoke recruitment and retention services, has unveiled its new patient scheduling tool to manage, report and track clinical trial projects in real time.
MRN-SMART incorporates a digital pen data capture facility, ensuring all source data compiled in the patient’s home is rapidly transmitted to the clinical trial site.
When MRN’s nurses visit patients in the home they can complete their records forms as usual however now data is now also automatically stored electronically on a central network which provides automatic tracking, enhanced visibility of trial data and increased security.
Dr Graham Wylie, CEO of MRN, commented: “We always strive for efficiency and effectiveness in all that we do. We work to defined quality management systems and are continually developing our tools to truly globalise the delivery ofhomecare in clinical trials.
“With MRN-SMART we offer greater security, real-time access to trial information and create cost savings.”
MRN-SMART is part of the MRN INNOVATION suite of tools and integrates with MRN-TEC, an interactive online portal offering study-specific and GCP training for nurses within MRN projects. The suite gives MRN a unique capability to train and manage large teams across the globe. Completing the MRN-INNOVATION suite isMRN-COMPLY, a quality and compliance system ensuring high standards of careacross all global trials.
Dr Wylie added: “I’m delighted to be launching MRN-SMART; it’s going to significantly help to combat the challenges posed by operating clinical trials across multiple timelines, numerous continents and time zones.”
MRN will officially launch MRN-SMART at the DIA Annual Meeting in Philadelphia next week on booth #2745. For further information on MRN-SMART and the MRN-INNOVATION suite of tools visit www.themrn.co.uk.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.